Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD

S. K. Tey; S. Vuckovic; A. Varelias; J. P. Martins; S. Olver; L. Samson; E. Sturgeon; J. Leach; J. Avery; M. Nakagaki; J. P. Butler; C. Curley; A. J. Morton; S. T. Durrant; G. A. Kennedy; G. R. Hill

ArticleOPEN ACCESS

Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD

Tey S
Vuckovic S
Varelias A
et al.

Bone Marrow Transplantation

DOI: 10.1038/bmt.2016.83

2Citations

9Readers

Get full text

Cite

CITATION STYLE

APA

Tey, S. K., Vuckovic, S., Varelias, A., Martins, J. P., Olver, S., Samson, L., … Hill, G. R. (2016, August 1). Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD. Bone Marrow Transplantation. Nature Publishing Group. https://doi.org/10.1038/bmt.2016.83

Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD

Cite

Register to see more suggestions